Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.26
-0.0100-0.79%
Pre-market: 1.24-0.0151-1.20%08:16 EDT
Volume:436.94K
Turnover:555.43K
Market Cap:71.28M
PE:-4.18
High:1.34
Open:1.28
Low:1.21
Close:1.27
Loading ...

The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing

Simply Wall St.
·
08 Jan

BRIEF-Icecure Medical Regains Full Nasdaq Compliance With Nasdaq Minimum Closing Bid Price Rule

Reuters
·
06 Jan

IceCure Medical Regains Nasdaq Compliance, Securing Market Position

TIPRANKS
·
06 Jan

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

PR Newswire
·
06 Jan

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires Live
·
04 Jan

IceCure Says European Patent Office Issues Intention to Grant Notice for Cryoablation System

MT Newswires Live
·
03 Jan

IceCure Medical Secures European Patent for Next-Generation Cryoablation Technology

TIPRANKS
·
03 Jan

IceCure Medical receives Intention to Grant notice from EPO

TIPRANKS
·
03 Jan

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

PR Newswire
·
03 Jan

Icecure Medical Appoints New Board Director with Financial Expertise

TIPRANKS
·
30 Dec 2024

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

PR Newswire
·
16 Dec 2024

IceCure Medical’s Cryoablation Success in Kidney Tumors

TIPRANKS
·
05 Dec 2024

BRIEF-IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results

Reuters
·
05 Dec 2024

IceCure Medical’s ProSense cryoablation shows efficacy in kidney tumor study

TIPRANKS
·
05 Dec 2024

Icecure's Prosense Cryoablation Safe, Effective in Kidney Tumors Destruction With 88.7% Recurrence-Free Rate Based on Interim Icesecret Study Results

THOMSON REUTERS
·
05 Dec 2024

Icecure Medical’s Strategic Position and Growth Potential Justifies Buy Rating

TIPRANKS
·
28 Nov 2024

Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.

Dow Jones
·
28 Nov 2024

Icecure Medical: Strong Growth and Regulatory Momentum Support Buy Rating

TIPRANKS
·
28 Nov 2024

IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
27 Nov 2024

IceCure Medical Sees Strong Growth Amid ProSense® Adoption

TIPRANKS
·
27 Nov 2024